QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
🧬Sex differences, EBV & MS: new insights from Nordic RWE
ECTRIMS kicks off today in Barcelona—the world’s largest multiple sclerosis conference.
Quantify is proud to contribute to two posters this year:
📍 P628 – Kelsi Smith (Quantify) presents her PhD research on sex differences in the genetic association between MC1R and MS risk.
📍 P068 – Moderna presents a Danish-Swedish observational study on MS risk linked to EBV (infectious mononucleosis), developed in collaboration with Jonas Banefelt […]
What’s it really like to be a project Leader at Quantify?
We asked our colleague Hannah Norman, Senior Project Leader in Market Access & HTA to share her experience.
💡What do project Leaders in Nordic Market Access and HTA actually do? “We help pharmaceutical companies bring life-saving and innovative medicines to market. The projects we manage range from small-scale assignments — such as a landscape analysis within a therapeutic area in one Nordic country, or gathering inputs for a health economic […]
🔁Autumn conference season: fully loaded
Where to find Quantify this autumn:
From Glasgow to San Diego, Berlin to Odense — our calendar is as packed as a health registry. We’re looking forward to impactful exchanges across RWE, HEOR, and access.
Where to find Quantify this autumn:
📍ECTRIMS– Sep 24-26, Barcelona
Kelsi Smith presents at Poster Session 2 on Sept 25:
Female-specific MS risk – A 9-year register-based study exploring sex differences in the melanocortin-1 receptor (MC1R) gene and MS.
Includes work […]
Quantify RWE Kick-off: Nordic Collaboration in Action!
This week, we are delighted to welcome our colleagues from Denmark and Finland to Stockholm as we kick off the fall period for the Real-World Evidence & Analytics unit. It’s a great opportunity for meetings, planning, and strengthening our overall collaboration and evidence generation.
💡Cross-office moments like these enable us to deliver trusted, local insights at scale – while having a lot of fun during the way!
[…]